Newsflash

LIFT Cancer Trial Starting in China
A new clinical trial based on Dr. Zheng Cui's granulocyte technology is starting at Beijing's 304 Hospital. Go to The LIFT Cancer Treatment Trial Site for more information.
CIK-DC: A New Antigen Bank Print

 

In June 2009, CCC unveiled it’s newest therapy: CIK-DC (cytokine-induced killer cells combined with dendritic cells). On its own, CIK is still an excellent tool against cancer: it fights and kills cancer cells systemically, boosts and restores the body’s own immune system (especially after the harsh, depleting effects of chemotherapy), and prevents metastasis and recurrence. What do DC cells do? DC cells give CIK a boost that allows CIK cells to more effectively target the location of cancer cells. Cultured from umbilical cord blood, the DC cells are especially potent at assisting CIK cells to protect the body while killing cancer cells. 

 

A helpful analogy: If CIK cells were the police, cancer cells are the criminals. On its own, the police (CIK) are effective and capable of fighting criminals and preventing the criminals from causing harm (cancer). However, the police would always appreciate a little help from police dogs (DC) who can make the process of catching criminals quicker and more accurate. The police dogs sniff the scent of criminals (antigens- the toxin given off by cancer cells that cause the body’s immune system to attack it), thus leading the police to the location of the criminals.

Before the advancements CCC has made with its use of a new generation of CIK-DC therapy, CIK-DC could only be performed on very early-stage cancer patients. However, at CCC we have recently been able to extend the benefits of CIK-DC to even middle and late-stage cancers by creating an antigen bank. By keeping a bank of the antigens that are given off by each kind of cancer, doctors can induce the CIK-DC to begin attacking a patient’s particular cancer before the injection of CIK-DC cells enters the body.


Previously, oncologists needed a biopsy of the patient’s cancer before treatment could begin since DC cells needed this biopsy sample in order to know which type of cancer they were expected to attack, and how to attack it. By requiring a biopsy, the treatment process had the disadvantages of causing more pain from surgery, more post-operation healing, more time, and more uncertainty. By creating an antigen bank--as well as having the potency of umbilical cord blood sourced DC-- these factors allow the CIK-DC combination to be far more effective, extending the benefits of this therapy to even late-stage cancers.

Last Updated on Wednesday, 25 August 2010 18:21